Introduction: Wave Life Sciences at Oppenheimer 2026
Wave Life Sciences Ltd, a pioneering clinical-stage biotechnology company dedicated to unlocking the transformative potential of RNA medicines, has announced a landmark participation at one of the most prestigious gatherings in the healthcare investment world. Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences, is scheduled to take part in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 2:40 p.m. ET.
This participation marks a significant moment for Wave Life Sciences as it continues to accelerate its RNA-based drug development pipeline and engage the investment community on its growing portfolio of clinical and preclinical programs. The Oppenheimer Healthcare Life Sciences Conference is widely regarded as a key platform where biotech and life sciences executives connect directly with institutional investors, analysts, and healthcare stakeholders.
About the Oppenheimer Healthcare Life Sciences Conference
What Makes This Conference a Major Industry Event
The Oppenheimer Annual Healthcare Life Sciences Conference, now in its 36th year, is one of the most respected forums in the healthcare investment sector. Hosted virtually, the event convenes leading executives from biotechnology, pharmaceutical, and medical device companies alongside institutional investors and equity analysts. It provides a unique opportunity for clinical-stage companies like Wave Life Sciences to present their scientific vision, pipeline progress, and long-term investment thesis directly to the financial community.
For companies operating at the frontier of genomic medicine and RNA therapeutics, participation in such high-profile events signals both scientific credibility and investor confidence. Wave Life Sciences’ inclusion underscores its growing relevance in the RNA medicines landscape.
Wave’s PRISM® RNA Medicines Platform Explained
A Breakthrough Approach to Treating Disease at the RNA Level
At the heart of Wave Life Sciences’ scientific strategy is its proprietary PRISM® platform — a multi-modal RNA medicines engine that combines chemistry innovation, multiple therapeutic modalities, and deep human genetics insights. PRISM® enables Wave to design and sustainably deliver RNA-targeting drug candidates that directly address the underlying biology of both rare and common diseases.
The platform’s toolkit includes two core modalities:
RNAi via SpiNA technology — engineered to silence disease-causing genes with high precision, reducing harmful protein production at the source.
RNA Editing via AIMers — a cutting-edge approach that corrects disease-causing mutations at the RNA level without permanently altering DNA, offering a potentially reversible and safer therapeutic option.
This dual-modality approach gives Wave unmatched flexibility in designing optimized drug candidates, and PRISM® continues to generate a rich pipeline of programs across multiple disease areas.
Key Pipeline Programs Driving Wave’s Innovation
Obesity and Liver Disease Programs
Wave Life Sciences has strategically positioned itself in some of the most commercially significant disease categories in modern medicine. Its lead programs include:
WVE-007 (Obesity): Targeting a novel genetic pathway associated with fat metabolism, WVE-007 represents Wave’s entry into the high-growth obesity therapeutics market, which has drawn enormous industry and investor attention in recent years.
WVE-006 (Alpha-1 Antitrypsin Deficiency / AATD): This program aims to address the genetic root cause of AATD, a rare inherited disorder that can lead to severe lung and liver damage. Wave’s RNA editing approach holds the potential to correct the underlying mutation rather than merely manage symptoms.
WVE-008 (PNPLA3 I148M Liver Disease): Targeting a well-validated genetic risk factor for non-alcoholic fatty liver disease (NAFLD) and related liver conditions, WVE-008 represents a precision medicine approach to a disease affecting millions globally.
Rare Disease Programs: DMD and Huntington’s Disease
Beyond its metabolic and liver disease programs, Wave maintains active clinical programs in Duchenne Muscular Dystrophy (DMD) — a devastating progressive muscle disorder primarily affecting young males — and Huntington’s disease, a fatal neurodegenerative condition. These programs showcase the broad applicability of the PRISM® platform across entirely different biological systems and disease mechanisms.
In addition to these clinical-stage efforts, Wave is advancing several preclinical programs that further demonstrate the platform’s versatility and the company’s commitment to building a durable, multi-asset pipeline.
Why Investors Should Watch Wave Life Sciences
A Compelling Story at the Intersection of Genetics and Medicine
Wave Life Sciences occupies a unique position at the convergence of genomics, RNA biology, and clinical drug development. Its diversified pipeline — spanning obesity, rare liver disease, neuromuscular disorders, and neurodegeneration — reduces single-program risk while maximizing the commercial potential of the PRISM® platform.
The company’s CEO-led participation at the Oppenheimer conference provides investors with a direct opportunity to assess Wave’s strategic direction, pipeline milestones, and near-term catalysts. With RNA medicine emerging as one of the most dynamic sectors in biotechnology, Wave’s platform-driven approach positions it as a compelling long-term investment proposition.
How to Access the Live Webcast
Join the Fireside Chat in Real Time
Investors, analysts, and healthcare professionals can access the live webcast of Paul Bolno’s fireside chat through the “Investor Events” section on the Wave Life Sciences website at ir.wavelifesciences.com/events-publications/events. A replay of the presentation will also be archived and made available on the site for a limited time following the event, allowing those unable to attend live to review the discussion at their convenience.
